乳酸脱氢酶A
癌症研究
厌氧糖酵解
生物
糖酵解
转移
三阴性乳腺癌
髓源性抑制细胞
髓样
自噬
癌细胞
癌症
免疫学
乳腺癌
内分泌学
抑制器
细胞凋亡
生物化学
新陈代谢
遗传学
作者
Wei Li,Takashi Tanikawa,Ilona Kryczek,Houjun Xia,Gaopeng Li,Ke Wu,Shuang Wei,Lili Zhao,Linda Vatan,Bo Wen,Shu Pan,Duxin Sun,Celina G. Kleer,Max S. Wicha,Michael S. Sabel,Kaixiong Tao,Guobin Wang,Weiping Zou
出处
期刊:Cell Metabolism
[Cell Press]
日期:2018-05-24
卷期号:28 (1): 87-103.e6
被引量:353
标识
DOI:10.1016/j.cmet.2018.04.022
摘要
Myeloid-derived suppressor cells (MDSCs) inhibit anti-tumor immunity. Aerobic glycolysis is a hallmark of cancer. However, the link between MDSCs and glycolysis is unknown in patients with triple-negative breast cancer (TNBC). Here, we detect abundant glycolytic activities in human TNBC. In two TNBC mouse models, 4T1 and Py8119, glycolysis restriction inhibits tumor granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) expression and reduces MDSCs. These are accompanied with enhanced T cell immunity, reduced tumor growth and metastasis, and prolonged mouse survival. Mechanistically, glycolysis restriction represses the expression of a specific CCAAT/enhancer-binding protein beta (CEBPB) isoform, liver-enriched activator protein (LAP), via the AMP-activated protein kinase (AMPK)-ULK1 and autophagy pathways, whereas LAP controls G-CSF and GM-CSF expression to support MDSC development. Glycolytic signatures that include lactate dehydrogenase A correlate with high MDSCs and low T cells, and are associated with poor human TNBC outcome. Collectively, tumor glycolysis orchestrates a molecular network of the AMPK-ULK1, autophagy, and CEBPB pathways to affect MDSCs and maintain tumor immunosuppression.
科研通智能强力驱动
Strongly Powered by AbleSci AI